Sandra Milligan's most recent trade in Gossamer Bio Inc was a trade of 26,050 Common Stock done at an average price of $1.9 . Disclosure was reported to the exchange on Aug. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gossamer Bio Inc | Sandra Milligan | Director | Purchase of securities on an exchange or from another person at price $ 1.92 per share. | 19 Aug 2025 | 26,050 | 58,050 (0%) | 0% | 1.9 | 50,016 | Common Stock |
| Gossamer Bio Inc | Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc. | Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Aspira Women`s Health Inc | Sandra Milligan | Interim CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Aspira Women`s Health Inc | Sandra Milligan | Interim CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 20,000 | 0 | - | - | Restricted Stock Units | |
| Aspira Women`s Health Inc | Sandra Milligan | Interim CEO | 31 Dec 2024 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | ||
| Aspira Women`s Health Inc | Sandra Milligan | Interim CEO | 31 Dec 2024 | 20,000 | 0 | - | - | Restricted Stock Units | ||
| Aspira Women`s Health Inc | Sandra Milligan | Interim CEO | 31 Dec 2024 | 6,356 | 13,644 (0%) | 0% | 0.7 | 4,449 | Common Stock | |
| Aspira Women`s Health Inc | Sandra Milligan | President | 12 Nov 2024 | 25,000 | 25,000 | - | - | Stock option (right to buy) | ||
| Aspira Women`s Health Inc | Sandra Milligan | President | 28 Oct 2024 | 20,000 | 20,000 | - | - | Restricted Stock Units | ||
| Gossamer Bio Inc | Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 115,000 | 115,000 | - | - | Non-qualified stock option (Right to Buy) | |
| Spyre Therapeutics Inc. | Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 21,980 | 21,980 | - | - | Stock Option (Right to Buy) | |
| Aspira Women`s Health Inc | Sandra Milligan | President | 03 May 2024 | 30,000 | 30,000 | - | - | EMPLOYEE STOCK OPTION (RIGHT TO BUY) | ||
| Gossamer Bio Inc | Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 4,984 | 4,984 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 4,984 | 30,767 | - | - | Common Stock | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.24 per share. | 04 May 2023 | 2,168 | 28,599 | - | 24.2 | 52,552 | Common Stock |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 1,899 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 1,899 | 26,609 | - | - | Common Stock | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.63 per share. | 01 May 2023 | 826 | 25,783 | - | 24.6 | 20,344 | Common Stock |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 104,961 | 104,961 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 29,230 | 29,230 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 5,964 | 26,825 | - | 0 | Common Stock | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 5,964 | 11,928 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.09 per share. | 31 Mar 2023 | 2,115 | 24,710 | - | 23.1 | 48,835 | Common Stock |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 7,976 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 7,976 | 23,207 | - | - | Common Stock | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.09 per share. | 28 Feb 2023 | 2,346 | 20,861 | - | 25.1 | 58,861 | Common Stock |
| Gossamer Bio Inc | Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 4,984 | 4,984 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 4,984 | 17,037 | - | - | Common Stock | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 1,842 | 12,578 | - | - | Common Stock | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 1,842 | 1,842 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.44 per share. | 03 May 2022 | 1,806 | 15,231 | - | 32.4 | 58,587 | Common Stock |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.08 per share. | 03 May 2022 | 525 | 12,053 | - | 32.1 | 16,842 | Common Stock |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2022 | 1,896 | 1,896 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2022 | 1,896 | 11,276 | - | - | Common Stock | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.33 per share. | 01 May 2022 | 540 | 10,736 | - | 32.3 | 17,458 | Common Stock |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 55,114 | 55,114 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 17,892 | 17,892 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 10,171 | 0 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 10,171 | 12,321 | - | - | Common Stock | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.57 per share. | 28 Feb 2022 | 2,941 | 9,380 | - | 37.6 | 110,493 | Common Stock |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 22,321 | 22,321 | - | - | Stock Option (Right to Buy) | |
| Gossamer Bio Inc | Sandra Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 47,000 | 47,000 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 115,980 | 115,980 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 63,054 | 63,054 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 53,919 | 53,919 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 48,931 | 48,931 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 44,503 | 44,503 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 41,588 | 41,588 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 19,828 | 19,828 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 14,957 | 14,957 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 10,170 | 10,170 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 7,975 | 7,975 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 3,795 | 3,795 | - | - | Restricted Stock Units | |
| Organon & Co. | Sandra Milligan | Head of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 1,842 | 1,842 | - | - | Restricted Stock Units |